Patents by Inventor Michael John LAMBRECHT

Michael John LAMBRECHT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • LACTAMS AS CBL-B INHIBITORS
    Publication number: 20250230147
    Abstract: Various lactam compound that binds Cbl-B, many of which are selective for Cbl-B over C-Cbl, and methods of making and using the same.
    Type: Application
    Filed: November 6, 2024
    Publication date: July 17, 2025
    Applicant: Genentech, Inc.
    Inventors: Jun Liang, Araz Jakalian, Michael John Lambrecht, Robin Larouche-Gauthier, Malcolm Huestis, Man Un Ung, Xiaojing Wang, Arun Yadav, Jason Robert Zbieg, Fabio Broccatelli
  • Lactams as CBL-B inhibitors selective over C-CBL
    Patent number: 12187709
    Abstract: A compound, of formula (I): suitable for treating a cancer wherein the cancer is susceptible to inhibition of Cbl-B.
    Type: Grant
    Filed: November 4, 2022
    Date of Patent: January 7, 2025
    Assignee: Genentech, Inc.
    Inventors: Malcolm Huestis, Michael John Lambrecht, Jun Liang, Man Un Ung, Xiaojing Wang, Jason Robert Zbieg, Bing-Yan Zhu, Lisa Marie Barton, Fabio Broccatelli, Georgette Marie Castanedo, Araz Jakalian, Robin Larouche-Gauthier, Arun Yadav
  • AMIDES AS CBL-B INHIBITORS
    Publication number: 20240300927
    Abstract: Various amide compounds that bind Cbl-B, including those that are selective for C-Cbl, and methods of making and using the same.
    Type: Application
    Filed: February 3, 2022
    Publication date: September 12, 2024
    Applicant: Genentech, Inc.
    Inventors: Jun Liang, Araz Jakalian, Michael John Lambrecht, Robin Larouche-Gauthier, Malcolm Huestis, Man Un Ung, Xiaojing Wang, Arun Yadav, Jason Robert Zbieg, Fabio Broccatelli
  • LACTAMS AS CBL-B INHIBITORS SELECTIVE OVER C-CBL
    Publication number: 20230212153
    Abstract: A compound, of formula (I): suitable for treating a cancer wherein the cancer is susceptible to inhibition of Cbl-B.
    Type: Application
    Filed: November 4, 2022
    Publication date: July 6, 2023
    Applicant: Genentech, Inc.
    Inventors: Malcolm HUESTIS, Michael John LAMBRECHT, Jun LIANG, Man Un UNG, Xiaojing WANG, Jason Robert ZBIEG, Bing-Yan Zhu, Lisa Marie BARTON, Fabio BROCCATELLI, Georgette Marie CASTANEDO, Araz JAKALIAN, Robin LAROUCHE-GAUTHIER, Arun YADAV
  • LACTAMS AS CBL-B INHIBITORS
    Publication number: 20230079990
    Abstract: Various lactam compound that binds Cbl-B, many of which are selective for Cbl-B over C-Cbl, and methods of making and using the same.
    Type: Application
    Filed: February 3, 2022
    Publication date: March 16, 2023
    Applicant: Genentech, Inc.
    Inventors: Jun LIANG, Araz JAKALIAN, Michael John LAMBRECHT, Robin LAROUCHE-GAUTHIER, Malcolm HUESTIS, Man Un UNG, Xiaojing WANG, Arun YADAV, Jason Robert ZBIEG, Fabio BROCCATELLI